News and Announcements
TokenOne Selected for a Consortium Project in the US
- Published August 31, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
TokenOne, a Sydney-based cybersecurity firm is now the first Australian company to be selected for a consortium project for the US National Cybersecurity Centre of Excellence.
KEY TAKEAWAYS:
- The Multifactor Authentication (MFA) for e-Commerce project will put transaction security in the spotlight
- The aim is to steer discussion away from passwords and to alternatives such as multifactor authentication
- Callsign, CA Technologies, Rivetz, RSA, Splunk, TokenOne, and Yubico are all collaborators in the project
- TokenOne plans to expand worldwide and says the NCCoE project is a huge milestone
- TokenOne is backed by investors such as Singtel Innov8. Retired FBI assistant director Charles Archer sits on the company’s advisory board
“Consumers, retailers, payment processors, banks, and card issuers are all impacted by fraud. Part of e-commerce fraud reduction includes an increased level of assurance in purchaser or user identity,” comments NCCoE’s Sarah Kinling.
“Retailers recognize that customers could be put off by the complexity that multifactor authentication mechanisms may add to the purchasing checkout and post transaction processes,” Kinling continues.
“Multiple forms of multifactor authenticators, such as FIDO, out-of-band, and one-time-password devices will be considered to provide retailers and their customers a diverse set of implementation options. All products incorporated into the reference design will be standards-based commercially available and open source products,” Kinling explains.
TokenOne’s technology allows businesses, customers and individuals to access services through a unique PIN that is visible to nobody else, including the service that is being accessed. No algorithms are involved.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
